Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.

Kenessey, István; Kramer, Zsófia; István, Lilla; Cserepes, Mihály T; Garay, Tamás; Hegedus, Balázs; Dobos, Judit; Tímár, József; Tóvári, József

Kenessey, István; Kramer, Zsófia; István, Lilla; Cserepes, Mihály T; Garay, Tamás; Hegedus, Balázs; Dobos, Judit; Tímár, József; Tóvári, József.

Afiliação

Kenessey I; 2nd Department of Pathology, Semmelweis University.
Kramer Z; Hungarian Cancer Registry, National Institute of Oncology.
István L; 2nd Department of Pathology, Semmelweis University.
Cserepes MT; 2nd Department of Pathology, Semmelweis University.
Garay T; Department of Experimental Pharmacology, National Institute of Oncology.
Hegedus B; Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences.
Dobos J; Semmelweis University.
Tímár J; 2nd Department of Pathology, Semmelweis University.
Tóvári J; Hungarian Academy of Sciences, Molecular Oncology Research Group, Semmelweis University.

Melanoma Res ; 28(6): 536-546, 2018 12.

Article em En | MEDLINE | ID: mdl-30124539

Assuntos

Antineoplásicos/uso terapêutico; Receptores ErbB/antagonistas & inibidores; Melanoma/tratamento farmacológico; Vemurafenib/uso terapêutico; Animais; Antineoplásicos/farmacologia; Humanos; Melanoma/genética; Melanoma/patologia; Camundongos; Camundongos SCID; Vemurafenib/farmacologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Receptores ErbB / Vemurafenib / Melanoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Melanoma Res Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google